CFO sold ~$397K of Gilead Sciences
Scheduled in advanceLoading…
Traded Apr 28, 2026 · Filed Apr 29, 2026
The boss of Gilead Sciences sold $895K of Gilead Sciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$895,075
Shares × reported transaction price
77 days after results of Feb 10, 2026, 9 days before results of May 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $129.26 on Apr 28, 2026, 33% above its 52-week low and 17% below its high, after an 11% drop over the previous 30 trading days
52-week range $96.91 (May 9, 2025) to $155.80 (Feb 11, 2026), 55% of the way up, from 251 adjusted closes. 30 trading days earlier: $145.21 on Mar 16, 2026. Describes the past only, not a forecast
A WARN layoff notice covering 108 workers was filed in California on April 30, 2026.
From the official state WARN list, 2 days after the trade; 1 more notice by the company within 60 days. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Hepcludex on May 22, 2026, 24 days after this trade.
Biologic approved. Active ingredient: Bulevirtide-Gmod. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.5% | +1.8% | +0.7% |
| 30 days | +0.2% | +5.5% | -5.3% |
| 90 days | +1.4% | +1.5% | -0.1% |
Past results only. Not a forecast.
CFO sold ~$397K of Gilead Sciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Officer sold ~$1.01M of Gilead Sciences
Scheduled in advance